EOLS Quote, Financials, Valuation and Earnings

GB Sciences, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of --. Evolus, Inc.'s return on equity of -5666.82% beat GB Sciences, Inc.'s return on equity of --.

Evolus, Inc. has a consensus price target of $15.17, signalling upside risk potential of 247.06%. On the other hand GB Sciences, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Evolus, Inc. has higher upside potential than GB Sciences, Inc., analysts believe Evolus, Inc. is more attractive than GB Sciences, Inc..

Evolus, Inc. has a beta of 1.114, which suggesting that the stock is 11.377% more volatile than S&P 500. In comparison GB Sciences, Inc. has a beta of 11.330, suggesting its more volatile than the S&P 500 by 1032.978%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. GB Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. GB Sciences, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than GB Sciences, Inc. quarterly revenues of --. Evolus, Inc.'s net income of -$15.7M is lower than GB Sciences, Inc.'s net income of -$190.5K. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while GB Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 0.98x versus 1.26x for GB Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Iovance Biotherapeutics, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -135.28%. Evolus, Inc.'s return on equity of -5666.82% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Evolus, Inc. has a consensus price target of $15.17, signalling upside risk potential of 247.06%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 217.46%. Given that Evolus, Inc. has higher upside potential than Iovance Biotherapeutics, Inc., analysts believe Evolus, Inc. is more attractive than Iovance Biotherapeutics, Inc..

Evolus, Inc. has a beta of 1.114, which suggesting that the stock is 11.377% more volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Evolus, Inc.'s net income of -$15.7M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 0.98x versus 3.80x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protokinetix, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of --. Evolus, Inc.'s return on equity of -5666.82% beat Protokinetix, Inc.'s return on equity of -111.59%.

Evolus, Inc. has a consensus price target of $15.17, signalling upside risk potential of 247.06%. On the other hand Protokinetix, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Evolus, Inc. has higher upside potential than Protokinetix, Inc., analysts believe Evolus, Inc. is more attractive than Protokinetix, Inc..

Evolus, Inc. has a beta of 1.114, which suggesting that the stock is 11.377% more volatile than S&P 500. In comparison Protokinetix, Inc. has a beta of 0.614, suggesting its less volatile than the S&P 500 by 38.569%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protokinetix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Protokinetix, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Protokinetix, Inc. quarterly revenues of --. Evolus, Inc.'s net income of -$15.7M is lower than Protokinetix, Inc.'s net income of -$84.9K. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Protokinetix, Inc.'s PE ratio is 23.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 0.98x versus -- for Protokinetix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of -22.82% compared to Evolus, Inc.'s net margin of -316.61%. Evolus, Inc.'s return on equity of -5666.82% beat Plus Therapeutics, Inc.'s return on equity of --.

Evolus, Inc. has a consensus price target of $15.17, signalling upside risk potential of 247.06%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1900%. Given that Plus Therapeutics, Inc. has higher upside potential than Evolus, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Evolus, Inc..

Evolus, Inc. has a beta of 1.114, which suggesting that the stock is 11.377% more volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Evolus, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evolus, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Evolus, Inc. quarterly revenues are $69M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Evolus, Inc.'s net income of -$15.7M is lower than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Evolus, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evolus, Inc. is 0.98x versus 4.41x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.